Skip to main content
. 2014 Oct 31;9(1):355–364. doi: 10.3892/ol.2014.2653

Table V.

Clinical and pathological characteristics of the patients with high/high-intermediate risk endometrioid histological subtype of endometrial cancer.

Lymphadenectomy

Variable Pelvic, n=19 Pelvic and para-aortic, n=48 P-value
Median age at surgery, years (IQR) 62 (52–70) 62 (54–67) 0.600
Histologic subtype, n (%)
 Endometrioid, pure 10 (52.6) 20 (41.7) 0.420a
 Endometrioid, with squamous differentiation 9 (47.4) 28 (58.3)
 Endometrioid, villoglandular variant 0 (0.0) 0 (0.0)
 Endometrioid, ciliated cell variant 0 (0.0) 0 (0.0)
FIGO stage, n (%)
 IA 3 (15.8) 2 (4.2) 0.100b
 IB 12 (63.2) 18 (37.5)
 II 0 (0.0) 4 (8.3)
 IIIA 0 (0.0) 3 (6.2)
 IIIC 4 (21.0) 19 (39.6)
 IVB 0 (0.0) 2 (4.2)
Grade, n (%)
 I 3 (15.8) 9 (18.8) 0.170c
 II 14 (73.7) 24 (50.0)
 III 2 (10.5) 15 (31.2)
Myometrial invasion, n (%)
 <1/2 4 (21.0) 6 (12.5) 0.450
 ≥1/2 15 (78.9) 42 (87.5)
Lymphovascular invasion, n (%) 6 (31.6) 19 (39.6) 0.540
Median tumor size, cm (IQR) 3.5 (3.0–4.0) 3.5 (2.5–5.3) 0.600
Peritoneal cytology positive, n (%) 2 (10.5) 2 (4.2) 0.320
Surgery, n (%)
 Laparoscopy 5 (26.3) 4 (8.3) 0.110
 Laparotomy 14 (73.7) 44 (91.7)
Median lymph nodes removed, n (IQR)
 Pelvic lymph nodes 27 (17–32) 26 (22–32) 0.600
 Paraaortic lymph nodes 0 (0.0) 13 (8–20) <0.001
Adjuvant treatment, n (%)
 None 1 (5.3) 2 (4.2) 0.210a
 Radiotherapy alone 15 (78.9) 24 (50.0)
 Chemotherapy alone 0 (0.0) 2 (4.2)
 Chemotherapy and radiotherapy 2 (10.5) 14 (29.1)
 Unknown 1 (5.3) 6 (12.5)
Median follow-up time, months (95% CI) 39 (34.29–57.40) 39 (28.60–40.44) 0.140

IQR, interquartile range; FIGO, International Federation of Gynaecology and Obstetrics; CI, confidence interval. P-values following the Bonferroni correction were a0.0125, b0.0083 and c0.0167.